View Financial HealthAvecho Biotechnology 配当と自社株買い配当金 基準チェック /06Avecho Biotechnology配当金を支払った記録がありません。主要情報n/a配当利回り-19.1%バイバック利回り総株主利回り-19.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 25Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026. Location: grant thornton, collins square, tower 5, level 22, 727 collins stree, melbourne, vic 3008 Australiaお知らせ • Oct 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listingお知らせ • Apr 24Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025. Location: grant thornton offices at collins square, tower 5, level 22, 727 collins street, melbourne Australiaお知らせ • Mar 01Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024.お知らせ • Nov 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 536,803,333 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 471,004,997 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Transaction Features: Subsequent Direct Listingお知らせ • Jan 12Athenex Submits Avecho's Phytonadione to FDA Pre-INDAvecho Biotechnology Limited announced that its TPM®-enhanced Vitamin K (phytonadione) injectable product has been presented to the FDA by Athenex Pharmaceutical Division, LLC in a pre- Investigational New Drug (pre-IND) meeting request. Phytonadione (Vitamin K1) injections are used to treat bleeding or clotting problems caused by Vitamin K deficiency, reactions to certain medications, or other medical conditions that lead tothinning of the blood. It is routinely administered to infants at birth as a prophylactic, providing protection against bleeding, and in 2021 the US had an overall adult and pediatric approximate market size of USD 87 million, with over 4.9 million units sold. Phytonadione is an insoluble oil that requiresformulation with an emulsifying agent in order to dissolve the drug in a formulation suitable for injection. These excipients are typically hydrogenated castor oil (Cremophor EL) or polysorbate, both of which are associated with adverse side effects when given by injection. In lieu of the adverse excipients traditionally used, Athenex has interest in commercialising Avecho's phytonadione formulation, that uses TPM® to dissolve and solubilise the drug. The FDA's feedback to the pre-IND submission will define the amount of development work remaining before a New Drug Application (NDA) for the product could be filed with the FDA for formal review. If the FDA response to the pre-IND submission is generally favorable, and the remaining development work is commercially feasible, the parties will proceed to a license and development agreement to complete the phytonadione product development work for the NDA submission to the US FDA and product commercialisation. The final commercial terms of a subsequent agreement will be determined once FDA feedback is received.決済の安定と成長配当データの取得安定した配当: AVEF.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: AVEF.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Avecho Biotechnology 配当利回り対市場AVEF.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (AVEF.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (AVEF.F) (最長3年)n/a注目すべき配当: AVEF.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: AVEF.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: AVEF.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: AVEF.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/30 23:40終値2025/05/02 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Avecho Biotechnology Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関David StantonNomura Securities Co. Ltd.
お知らせ • Apr 25Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026Avecho Biotechnology Limited, Annual General Meeting, May 26, 2026. Location: grant thornton, collins square, tower 5, level 22, 727 collins stree, melbourne, vic 3008 Australia
お知らせ • Oct 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 500,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 24Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025Avecho Biotechnology Limited, Annual General Meeting, May 27, 2025. Location: grant thornton offices at collins square, tower 5, level 22, 727 collins street, melbourne Australia
お知らせ • Mar 01Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024.
お知らせ • Nov 23Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 536,803,333 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 471,004,997 Price\Range: AUD 0.006 Discount Per Security: AUD 0.00036 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 12Athenex Submits Avecho's Phytonadione to FDA Pre-INDAvecho Biotechnology Limited announced that its TPM®-enhanced Vitamin K (phytonadione) injectable product has been presented to the FDA by Athenex Pharmaceutical Division, LLC in a pre- Investigational New Drug (pre-IND) meeting request. Phytonadione (Vitamin K1) injections are used to treat bleeding or clotting problems caused by Vitamin K deficiency, reactions to certain medications, or other medical conditions that lead tothinning of the blood. It is routinely administered to infants at birth as a prophylactic, providing protection against bleeding, and in 2021 the US had an overall adult and pediatric approximate market size of USD 87 million, with over 4.9 million units sold. Phytonadione is an insoluble oil that requiresformulation with an emulsifying agent in order to dissolve the drug in a formulation suitable for injection. These excipients are typically hydrogenated castor oil (Cremophor EL) or polysorbate, both of which are associated with adverse side effects when given by injection. In lieu of the adverse excipients traditionally used, Athenex has interest in commercialising Avecho's phytonadione formulation, that uses TPM® to dissolve and solubilise the drug. The FDA's feedback to the pre-IND submission will define the amount of development work remaining before a New Drug Application (NDA) for the product could be filed with the FDA for formal review. If the FDA response to the pre-IND submission is generally favorable, and the remaining development work is commercially feasible, the parties will proceed to a license and development agreement to complete the phytonadione product development work for the NDA submission to the US FDA and product commercialisation. The final commercial terms of a subsequent agreement will be determined once FDA feedback is received.